ES2190469T3 - Derivados de isocumarina y su uso en farmacos. - Google Patents

Derivados de isocumarina y su uso en farmacos.

Info

Publication number
ES2190469T3
ES2190469T3 ES96917702T ES96917702T ES2190469T3 ES 2190469 T3 ES2190469 T3 ES 2190469T3 ES 96917702 T ES96917702 T ES 96917702T ES 96917702 T ES96917702 T ES 96917702T ES 2190469 T3 ES2190469 T3 ES 2190469T3
Authority
ES
Spain
Prior art keywords
isocumarine
pharmacos
derivatives
pharmaceutical preparations
vascularization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96917702T
Other languages
English (en)
Inventor
Shin-Ichi Hirano
Toshiyuki Mase
Naoki Agata
Hiroshi Iguchi
Naoki Matsumoto
Takeo Yoshioka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbial Chemistry Research Foundation
Mercian Corp
Original Assignee
Microbial Chemistry Research Foundation
Mercian Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbial Chemistry Research Foundation, Mercian Corp filed Critical Microbial Chemistry Research Foundation
Application granted granted Critical
Publication of ES2190469T3 publication Critical patent/ES2190469T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE FORMULA (I): DONDE R ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO C 1-6 Y N ES UN ENTERO DE VALOR 0 O 1, ASI COMO A PREPARACIONES FARMACEUTICAS DEL MISMO. DICHAS PREPARACIONES FARMACEUTICAS SON UTILES PARA LA PREVENCION O TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON UNA ANORMALIDAD EN LA FUNCION REGULADORA INMUNOLOGICA O DE VASCULARIZACION.
ES96917702T 1994-12-19 1996-06-17 Derivados de isocumarina y su uso en farmacos. Expired - Lifetime ES2190469T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP6333769A JPH08176138A (ja) 1994-12-19 1994-12-19 イソクマリン誘導体
CA002259621A CA2259621C (en) 1994-12-19 1996-06-17 Isocoumarin derivatives and their use in medicines
PCT/JP1996/001657 WO1997048693A1 (fr) 1994-12-19 1996-06-17 Derives d'isocoumarine et utilisation de ces derniers dans des medicaments

Publications (1)

Publication Number Publication Date
ES2190469T3 true ES2190469T3 (es) 2003-08-01

Family

ID=27170918

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96917702T Expired - Lifetime ES2190469T3 (es) 1994-12-19 1996-06-17 Derivados de isocumarina y su uso en farmacos.

Country Status (9)

Country Link
US (1) US6020363A (es)
EP (1) EP0930310B1 (es)
JP (2) JPH08176138A (es)
AT (1) ATE235482T1 (es)
AU (1) AU6017296A (es)
CA (1) CA2259621C (es)
DE (1) DE69627042T2 (es)
ES (1) ES2190469T3 (es)
WO (1) WO1997048693A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010001270A (ko) 1999-06-03 2001-01-05 복성해 혈관신생을 억제하는 새로운 이소쿠마린 유도체
ATE406359T1 (de) * 1999-07-22 2008-09-15 Mercian Corp Verfahren zum herstellen von isocoumarinen und zwischenprodukte hierfür
JP2001122870A (ja) * 1999-10-27 2001-05-08 Mercian Corp イソクマリン誘導体およびそれらの製造方法
US6473960B1 (en) 2000-01-07 2002-11-05 Storage Technology Corporation Method of making nitrided active elements
US6589981B2 (en) * 2000-02-29 2003-07-08 Ilex Oncology, Inc. Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives
US6900239B2 (en) * 2000-02-29 2005-05-31 Ilwz Ilex Products, Inc. Tumor chemopotentiation using isocoumarin derivatives
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
CN1455680A (zh) * 2000-09-11 2003-11-12 达纳-法伯癌症协会有限公司 Muc1胞外域和癌症治疗组合物及方法
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
US6740406B2 (en) * 2000-12-15 2004-05-25 Kimberly-Clark Worldwide, Inc. Coated activated carbon
US20040166248A1 (en) * 2000-12-15 2004-08-26 Sheng-Hsin Hu Coated activated carbon
WO2002058450A2 (en) * 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
WO2002062781A1 (fr) * 2001-02-02 2002-08-15 Mercian Corporation Preparation de derives d'isocoumarine et intermediaires pour leur synthese
US6664401B2 (en) 2001-07-06 2003-12-16 Ilex Products, Inc. Process for preparing isocoumarins
US20060122387A1 (en) * 2002-06-13 2006-06-08 Cti Europe S.R.L. Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
US20070202134A1 (en) * 2004-02-23 2007-08-30 Kufe Donald W Muc1 Antagonist Enhancement of Death Receptor Ligand-Induced Apoptosis
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
WO2008093855A1 (ja) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. 未分化型胃癌治療用組成物
WO2008097844A2 (en) * 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2586443B1 (en) 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
AU2014266223B2 (en) 2013-05-14 2020-06-25 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PL3524595T3 (pl) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2802097B2 (ja) * 1989-05-31 1998-09-21 財団法人微生物化学研究会 新規な制癌抗生物質ｍｉ４３―３７ｆ１１及びその製造法
JP3041022B2 (ja) * 1990-08-31 2000-05-15 メルシャン株式会社 抗性物質ｍ１４３―３７ｆ１１の製造方法及び製造中間体
JPH0597841A (ja) * 1991-10-04 1993-04-20 Mercian Corp イソクマリン誘導体
JP3233709B2 (ja) * 1992-12-18 2001-11-26 メルシャン株式会社 免疫調節剤

Also Published As

Publication number Publication date
EP0930310A4 (en) 2001-08-22
US6020363A (en) 2000-02-01
DE69627042T2 (de) 2003-11-20
ATE235482T1 (de) 2003-04-15
JPH08176138A (ja) 1996-07-09
EP0930310B1 (en) 2003-03-26
CA2259621C (en) 2007-09-18
EP0930310A1 (en) 1999-07-21
DE69627042D1 (de) 2003-04-30
AU6017296A (en) 1998-01-07
JP3150709B2 (ja) 2001-03-26
WO1997048693A1 (fr) 1997-12-24
CA2259621A1 (en) 1997-12-24

Similar Documents

Publication Publication Date Title
ES2190469T3 (es) Derivados de isocumarina y su uso en farmacos.
ATE142630T1 (de) Triazin-derivate und unkrautvertilgungsmittel daraus
DE69418243D1 (de) N-Heteroaryl-N'-Phenylharnstoffderivate, ihre Herstellung und Verwendung
DE69010139D1 (de) Haarkräftigungsmittel.
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
MX9204029A (es) Procedimiento de preparacion de un derivado de la bacatina iii y de la 10-desacetil bacatina iii
ATE212860T1 (de) Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
ES2091310T3 (es) Nuevos derivados de la n-benzoil-prolina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DE69222459T2 (de) Thiazolidindionderivate, ihre Herstellung und Anwendung
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
ATE22294T1 (de) Pyrido(3,4-c)psoralene, herstellung, verwendung in der kosmetologie und als arzneimittel und diese enthaltende zubereitungen.
DE3870167D1 (de) N-(vinblastinoyl-23)-derivate von 1-aminomethylposphonsaeure, verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
ATE184282T1 (de) Cyclopropan-derivate und diese enthaltende antivirale mittel
FI20021652A (fi) Tratsodonin alkyylijohdannaisten valmistuksessa käyttökelpoisia välituotteita
ATE97130T1 (de) 13-brom und 13, 14-dibrom-ergoline, ihre herstellung und verwendung in arzneimitteln.
DE3862660D1 (de) 2,3-dihydro-2-oxo-3-benzofuranyl-essigsaeurederivate und diese enthaltende arzneimittel.
SE9201188L (sv) Ny användning
DE68922596D1 (de) 3-(3-Ethyl-1,2,4-oxadiazol-5-yl)-1-azabicycloheptan, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zubereitungen.
FI933928A (fi) Heteroarenylpiperaziner, foerfarande foer framstaellning av dessa och anvaendning som laekemedel
NO178302C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte 3-tia- henholdsvis 3-oksa-alkylflavoner, samt mellomprodukter for fremgangsmåten
DE69419083T2 (de) Salmycine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE69112095D1 (de) 1-Phenoxycarbonyl-2-Pyrrolidon-Derivate und nootrope Wirkstoffe.